Hematology, Transfusion and Cell Therapy (Oct 2024)

THE DONOR EXPERIENCE IN THE VALIDATION OF NEW APHERESIS EQUIPMENT IN BRAZIL

  • CRA Silva,
  • G Dourado,
  • A Crispim,
  • B Menezes,
  • F Pimenta,
  • M Pina,
  • F Teixeira,
  • E Bariani,
  • C Bariani,
  • A Silva

Journal volume & issue
Vol. 46
pp. S914 – S915

Abstract

Read online

Background/case studies: Transfusion of platelet concentrates by apheresis is the first-line treatment for thrombocytopenic cancer patients undergoing chemotherapy. Maintaining a safe stock of this blood component is a challenge for blood banks, as collection time, possible adverse reactions during the procedure and the confidence transmitted by the equipment operator are factors that can discourage donation. Offering the donor an excellent collection experience implies a donation with adequate time and without incidents. A positive experience not only builds donor loyalty but also contributes to better use of the collection. This case study evaluated the donor experience as part of the validation process for a new apheresis machine in Brazil. Study design/methods: In March 2024, 40 donors with platelet counts greater than 200,000 cells/ul were selected for validation of the AmiCORE 2.1 equipment with the addition of Intersol (PAS). After collection, a questionnaire assessed the donor's experience, the intensity of perioral tingling and time in the equipment. The ideal responses were above “7”for the positive experience, below “4”for tingling and “adequate”or “short”for time on the equipment. The effectiveness of the collected platelet concentrate was evaluated by the A/T index, with the ideal value being at least 1. Results/findings: As for how pleasant it was to donate to this equipment, only 1 donor (2.5%) classified it as not very pleasant, the other 39 (98.5%) found it very pleasant, even when compared to other equipment. The average time spent in the equipment was 85 minutes and the 95% CI (80.5-89.6). The only donor who rejected the equipment was outside this confidence interval. The intensity of perioral tingling was characterized as low (levels 1, 2 and 3) in 39 donors (98.5%), the only case in which the intensity was severe and caused discomfort to the donor was the one in which the collection time was prolonged according to your perception. Regarding the success of collecting platelet concentrates by apheresis, the average A/T index was 1.1 and the CI was 95% (1-1.04). The equipment was approved by 39 (98.5%) donors and they stated that they would donate again. Conclusions: Donors’ perception was greater than 95%, except for the time spent in the equipment. One donor had severe paresthesia, which was treated by reducing the citrate perfusion rate. Although the length of stay was only 80% of what was expected, 95% of donors approved the equipment, reinforcing the importance of a welcoming environment. The equipment was recommended for incorporation into the service. Importance of research New blood collection equipment must be validated before use. Validation considers technical, operational and financial aspects. However, the donor experience is also crucial, influencing the quality of the blood component and decisions about acquiring new technologies. This study highlights the importance of donor experience in equipment validation.